| 1 | 1 | | I |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 1143 |
|---|
| 5 | 5 | | To amend title XVIII of the Social Security Act to expand coverage of |
|---|
| 6 | 6 | | the in-home administration of intravenous immune globulin under the |
|---|
| 7 | 7 | | Medicare program. |
|---|
| 8 | 8 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 9 | 9 | | FEBRUARY7, 2025 |
|---|
| 10 | 10 | | Mr. S |
|---|
| 11 | 11 | | MITHof Nebraska (for himself and Mr. GARAMENDI) introduced the fol- |
|---|
| 12 | 12 | | lowing bill; which was referred to the Committee on Energy and Com- |
|---|
| 13 | 13 | | merce, and in addition to the Committee on Ways and Means, for a pe- |
|---|
| 14 | 14 | | riod to be subsequently determined by the Speaker, in each case for con- |
|---|
| 15 | 15 | | sideration of such provisions as fall within the jurisdiction of the com- |
|---|
| 16 | 16 | | mittee concerned |
|---|
| 17 | 17 | | A BILL |
|---|
| 18 | 18 | | To amend title XVIII of the Social Security Act to expand |
|---|
| 19 | 19 | | coverage of the in-home administration of intravenous |
|---|
| 20 | 20 | | immune globulin under the Medicare program. |
|---|
| 21 | 21 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 22 | 22 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 23 | 23 | | SECTION 1. SHORT TITLE. 3 |
|---|
| 24 | 24 | | This Act may be cited as the ‘‘Medicare IVIG Access 4 |
|---|
| 25 | 25 | | Enhancement Act of 2025’’. 5 |
|---|
| 26 | 26 | | VerDate Sep 11 2014 18:26 Mar 07, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1143.IH H1143 |
|---|
| 27 | 27 | | ssavage on LAPJG3WLY3PROD with BILLS 2 |
|---|
| 28 | 28 | | •HR 1143 IH |
|---|
| 29 | 29 | | SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINIS-1 |
|---|
| 30 | 30 | | TRATION OF INTRAVENOUS IMMUNE GLOB-2 |
|---|
| 31 | 31 | | ULIN UNDER THE MEDICARE PROGRAM. 3 |
|---|
| 32 | 32 | | (a) I |
|---|
| 33 | 33 | | NGENERAL.—Section 1861 of the Social Secu-4 |
|---|
| 34 | 34 | | rity Act (42 U.S.C. 1395x) is amended— 5 |
|---|
| 35 | 35 | | (1) in subsection (s)(2)(Z), by inserting ‘‘(and, 6 |
|---|
| 36 | 36 | | beginning January 1, 2027, for the treatment of 7 |
|---|
| 37 | 37 | | chronic inflammatory demyelinating polyneuropathy 8 |
|---|
| 38 | 38 | | and multifocal motor neuropathy)’’ after ‘‘primary 9 |
|---|
| 39 | 39 | | immune deficiency diseases’’; and 10 |
|---|
| 40 | 40 | | (2) in subsection (zz), by inserting ‘‘(or, begin-11 |
|---|
| 41 | 41 | | ning January 1, 2027, with diagnosed chronic in-12 |
|---|
| 42 | 42 | | flammatory demyelinating polyneuropathy and 13 |
|---|
| 43 | 43 | | multifocal motor neuropathy)’’ after ‘‘primary im-14 |
|---|
| 44 | 44 | | mune deficiency disease’’. 15 |
|---|
| 45 | 45 | | (b) A |
|---|
| 46 | 46 | | UTHORITY FORVARIANCE INPAYMENTS.—Sec-16 |
|---|
| 47 | 47 | | tion 1842(o)(8) of the Social Security Act (42 U.S.C. 17 |
|---|
| 48 | 48 | | 1395u(o)(8)) is amended by inserting ‘‘and may vary de-18 |
|---|
| 49 | 49 | | pending on whether such administration is related to 19 |
|---|
| 50 | 50 | | treatment of a primary immune deficiency disease or the 20 |
|---|
| 51 | 51 | | treatment of chronic inflammatory demyelinating 21 |
|---|
| 52 | 52 | | polyneuropathy or multifocal motor neuropathy (as deter-22 |
|---|
| 53 | 53 | | mined appropriate by the Secretary through notice and 23 |
|---|
| 54 | 54 | | comment rulemaking)’’ after ‘‘of 2012’’. 24 |
|---|
| 55 | 55 | | Æ |
|---|
| 56 | 56 | | VerDate Sep 11 2014 18:26 Mar 07, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H1143.IH H1143 |
|---|
| 57 | 57 | | ssavage on LAPJG3WLY3PROD with BILLS |
|---|